Business
American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.’s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code
Obtaining a CPT PLA code marks a key milestone in securing reimbursement from federal and private payers for, and expanding access to the innovative
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":"\nObtaining a CPT PLA code marks a key milestone in securing reimbursement from federal and private payers for, and expanding access to the innovative PrecisionCHD test powered by AI and epigenetics\n\n\n CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced that the American Medical Association (AMA) has assigned a dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analysis (PLA), 0440U, for the company’s AI-driven coronary heart disease (CHD) detection test, PrecisionCHD. Receipt of this new CPT PLA code, which will be effective on April 1, 2024, is a significant step toward payer billing and payment, facilitating broader adoption of the first and only integrated genetic-epigenetic diagnostic blood test for CHD.\n\n\nTransforming CHD Diagnosis: The Clinical and Economic Benefits of PrecisionCHD\n\n\nCHD, which is the most common type of heart disease and the major cause of heart attacks, was responsible for over 375,000 deaths in 2021 and the medical costs associated with CHD are projected to reach about $215 billion by 2035. The PrecisionCHD test, which evaluates a patient’s unique genetic and epigenetic biomarkers and interprets them using AI, aims to aid in the diagnosis of CHD and provide personalized insights to help prevent a costly heart attack and improve outcomes.\n\n\nIdentifying those with CHD and intervening prior to a heart attack occurring are essential to reducing the unprecedented economic and health burden associated with CHD. However, the lack of readily accessible, scalable and cost-effective diagnostic solutions for CHD poses a significant challenge, and could lead to delayed diagnosis and care, particularly among underserved and minority populations. The PrecisionCHD test only requires a simple blood draw, can be deployed remotely, and be scaled without the need for specialized infrastructure to enable more timely intervention and management.\n\n\n“Cardio Diagnostics is committed to ensuring that our solutions are widely accessible and receiving a dedicated CPT PLA code for PrecisionCHD is a critical milestone in our commercialization strategy,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “With PrecisionCHD, we believe that expanding equitable access to CHD diagnostics...